The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Manturova N.E.

Kafedra plasticheskoĭ i ésteticheskoĭ khirurgii, kosmetologii i kletochnykh tekhnologiĭ GBOU VPO "Rossiĭskiĭ natsional'nyĭ issledovatel'skiĭ meditsinskiĭ universitet im. N.I. Pirogova" Minzdravsotsrazvitiia Rossii

Chajkovskaya E.A.

Institute of Plastic Surgery and Cosmetology, Moscow, Russia

Timerbaeva S.L.

Research Center of Neurology, Moscow, Russia

Botulinum toxin therapy: what do we have and what do we see on the horizon?

Authors:

Manturova N.E., Chajkovskaya E.A., Timerbaeva S.L.

More about the authors

Journal: Plastic Surgery and Aesthetic Medicine. 2020;(2): 70‑80

DOI: 10.17116/plast.hirurgia202002170

Read: 44668 times

Download PDF (RU)
Contact the author
Table of contents

BOTULINUM TOXIN THERAPY: WHAT DO WE HAVE AND WHAT DO WE SEE ON THE HORIZON?
BOTULINUM TOXIN THERAPY: WHAT DO WE HAVE AND WHAT DO WE SEE ON THE HORIZON?

To cite this article:

Manturova NE, Chajkovskaya EA, Timerbaeva SL. Botulinum toxin therapy: what do we have and what do we see on the horizon? Plastic Surgery and Aesthetic Medicine. 2020;(2):70‑80. (In Russ.)
https://doi.org/10.17116/plast.hirurgia202002170

Подписка 2026 Пластическая хирургия и эстетическая медицина (Plastic Surgery and Aesthetic Medicine)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Immu­nogenicity of botu­linum toxin products: the emergence of resi­stance and ways to overcome it. Plastic Surgery and Aesthetic Medi­cine. 2025;(1):125-134
Comparative analysis of the effe­ctiveness of Botu­linum toxin type A — hema­gglutinin preparations of the Rela­tox and Botox complex in the treatment of patients with primary idiopathic blepharospasm. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):86-90
Impact of botu­linum therapy on long-term control of cervical dystonia symptoms and patient sati­sfaction with treatment: resu­lts of the inte­rnational prospective obse­rvational study INTE­REST IN CD2 in Russian subgroup of patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):74-82
The effe­ctiveness of using a centrally acting muscle rela­xant in combination with botu­linum toxin inje­ctions in patients with spasmodic torticollis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):99-102
Dystonia caused by a muta­tion in the KMT2B gene. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(12):249-252
Abstract:

Botulinum therapy is the most relevant method of modern aesthetic medicine. The review article is devoted to the development and improvement of botulinum toxin preparations, including a new medicinal form — an injectable solution ready for use. The creation of new drugs of botulinum toxin meets the current tasks of clinical botulinotherapy: simplifying the work with the drug, creating fast and long-acting forms, minimizing the development of immunoresistance. The Russian Federation has developed and registered two drugs botulinum toxin a — relatox (lyophilized form) and miotox (injection solution).

Keywords:

botulinum therapy
botulinum toxin types A
E
C and D
«liquid toxin»
myotoxus
long-acting botulinum toxin
short-acting botulinum toxin
overcoming immunoresistance

Authors:

Manturova N.E.

Kafedra plasticheskoĭ i ésteticheskoĭ khirurgii, kosmetologii i kletochnykh tekhnologiĭ GBOU VPO "Rossiĭskiĭ natsional'nyĭ issledovatel'skiĭ meditsinskiĭ universitet im. N.I. Pirogova" Minzdravsotsrazvitiia Rossii

Chajkovskaya E.A.

Institute of Plastic Surgery and Cosmetology, Moscow, Russia

Timerbaeva S.L.

Research Center of Neurology, Moscow, Russia

Close metadata

References:

  1. The ABCs of the therapy. Ed. Timerbayeva S.L. M.: Prakticheskaya medicina; 2018. (In Russ.).
  2. Jankovic J. Botulinum toxin: State of the art. Mov Disord. 2017;32(8):1131-1138. https://doi.org/10.1002/mds.27072
  3. Samizadeh S, De Boulle K. Botulinum neurotoxin formulations: overcoming the confusion. Clin Cosmet Investig Dermatol. 2018;11:273-287. https://doi.org/10.2147/CCID.S156851
  4. Kim YS, Hong ES, Kim HS. Botulinum Toxin in the Field of Dermatology: Novel Indications. Toxins (Basel). 2017;9(12):403. https://doi.org/10.3390/toxins9120403
  5. Guida S, Farnetani F, Nisticò SP, et al. New trends in botulinum toxin use in dermatology. Dermatol Pract Concept. 2018;8(4):277-282. https://doi.org/10.5826/dpc.0804a05
  6. Sundaram H, Signorini M, Liew S, et al. Global Aesthetics Consensus: Botulinum Toxin Type A- Evidence-Based Review, Emerging Concepts, and Consensus Recommendations for Aesthetic Use, Including Updates on Complications. Plast Reconstr Surg. 2016;137(3):518e-529e. https://doi.org/10.1097/01.prs.0000475758.63709.23
  7. Wright G, Lax A, Mehta SB. A review of the longevity of effect of botulinum toxin in wrinkle treatments. Br Dent J. 2018;224(4):255-260. https://doi.org/10.1038/sj.bdj.2018.126
  8. Gendler E, Nagler A. Aesthetic use of BoNT: Options and outcomes. Toxicon. 2015;107(Pt A):120-128. https://doi.org/10.1016/j.toxicon.2015.08.023.
  9. Campanati A, Martina E, Giuliodori K, Consales V, Bobyr I, Offidani A. Botulinum toxin off-label use in dermatology: a review. Skin Appendage Disord. 2017;3(1):39–56. https://doi.org/10.1159/000452341
  10. Guida S, Farnetani F, Nisticò SP, et al. New trends in botulinum toxin use in dermatology. Dermatol Pract Concept. 2018;8(4):277-282. https://doi.org/10.5826/dpc.0804a05
  11. Kasyanju Carrero LM, Ma WW, Liu HF, Yin XF, Zhou Botulinum toxin type A for the treatment and prevention of hypertrophic scars and keloids: Updated review. BR.J Cosmet Dermatol. 2019;18(1):10-15. https://doi.org/10.1111/jocd.12828
  12. Dhawan A, Dhawan S, Vitarella D. The Potential Role of Botulinum Toxin in Improving Superficial Cutaneous Scarring: A Review. J Drugs Dermatol. 2018 Sep 1;17(9):956-958.
  13. Wang D, Qu J, Jiang H, Jiang Y. The safety and efficacy of botulinum toxin for management of scars: A systematic review with meta-analysis and trial sequential analysis. Toxicon. 2019;166:24-33. https://doi.org/10.1016/j.toxicon.2019.04.018
  14. Park KY, Hyun MY, Jeong SY, Kim BJ, Kim MN, Hong CK. Botulinum toxin for the treatment of refractory erythema and flushing of rosacea. Dermatology. 2015;230(4):299-301. https://doi.org/10.1159/000368773
  15. Gibbons JP, Nugent E, O’Donohoe N, Maher B, Egan B, Feeley M, Tierney S. Experience with botulinum toxin therapy for axillary hyperhidrosis and comparison to modelled data for endoscopic thoracic sympathectomy — A quality of life and cost effectiveness analysis. Surgeon. 2016;14(5):260-264. https://doi.org/10.1016/j.surge.2015.05.002.
  16. Shuo L, Ting Y, KeLun W, Rui Z, Rui Z, Hang W. Efficacy and possible mechanisms of botulinum toxin treatment of oily skin. J Cosmet Dermatol. 2019;18(2):451-457. https://doi.org/10.1111/jocd.12866
  17. Zhang L, Yu Q, Wang Y, Ma Y, Shi Y, Li X. A small dose of botulinum toxin A is effective for treating androgenetic alopecia in Chinese patients. Dermatol Ther. 2019;32(4):e12785. https://doi.org/10.1111/dth.12785
  18. Noland ME, Lalonde DH, Yee GJ, Rohrich RJ. Current Uses of Botulinum Neurotoxins in Plastic Surgery. Plast Reconstr Surg. 2016;138(3):519e-30e. https://doi.org/10.1097/PRS.0000000000002480
  19. Yu Y, Sun J, Shen Z, Lin X, Xu J. Auxiliary usage of botulinum toxin A in plastic surgery in China. J Cosmet Dermatol. 2020;19(5):1021-1028. https://doi.org/10.1111/jocd.13306
  20. Guo X, Jin X. The Use of Botulinum Toxin Type A in the Healing of Thyroidectomy Wounds: A Randomized, Prospective, Placebo-Controlled Study. Plast Reconstr Surg. 2019;144(6):1125e. https://doi.org/10.1097/PRS.0000000000006252
  21. Le Louarn C. Toxine botulique: un complément important à la chirurgie du rajeunissement facial (Botulinum toxin: An important complement for facial rejuvenation surgery). Ann Chir Plast Esthet. 2017;62(5):495-519. https://doi.org/10.1016/j.anplas.2017.07.007.
  22. Fu KJ, Teichgraeber JF, Greives MR. Botulinum Toxin Use in Pediatric Plastic Surgery. Ann Plast Surg. 2016;77(5):577-582. https://doi.org/10.1097/SAP.0000000000000637
  23. Shi N, Guo S, Su Y, Zhang Z, Qiu L, Yu Z, Yang Q, Wang N, Yi C. Improvement in the Retention Rate of Transplanted Fat in Muscle by Denervation. Aesthet Surg J. 2018;38(9):1026-1034. https://doi.org/10.1093/asj/sjy104.PMID: 29992230
  24. Dadaci M, Yildirim MEC, İnce B. Effects of Botulinum Toxin on Improving Facial Surgical Scars: A Prospective, Split-Scar, Double-Blind, Randomized Controlled Trial. Plast Reconstr Surg. 2019;143(1):237e-238e. https://doi.org/10.1097/PRS.0000000000005136.
  25. Hu Li, Zou Yun, Chang Shih-Jen, Qiu Yajing, Chen Hui, Gang Ma, Jin Yunbo, Lin Xiaoxi. Effects of Botulinum Toxin on Improving Facial Surgical Scars: A Prospective, Split-Scar, Double-Blind, Randomized Controlled Trial. Plastic and Reconstructive Surgery. 2018;141(3)6:646-650. https://doi.org/10.1097/PRS.0000000000004110
  26. Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. Pharmacol Rev. 2017;69(2):200-235. https://doi.org/10.1124/pr.116.012658
  27. Oh SH, Lee Y, Seo YJ, et al. The potential effect of botulinum toxin type A on human dermal fibroblasts: an in vitro study. Dermatol Surg. 2012;38(10): 1689-1694. https://doi.org/10.1111/j.1524-4725.2012.02504.x
  28. Wanitphakdeedecha R, Kaewkes A, Ungaksornpairote C, Limsaengurai S, Panich U, Manuskiatti W. The effect of botulinum toxin type A in different dilution on the contraction of fibroblast –I n vitro study. J Cosmet Dermatol. 2019;18(5):1215-1223. https://doi.org/10.1111/jocd.13058
  29. Zhang X, Lan D, Ning S, Jia H, Yu S. Botulinum toxin type A prevents the phenotypic transformation of fibroblasts induced by TGF-β1 via the PTEN/PI3K/Akt signaling pathway. Int J Mol Med. 2019;44(2):661-671. https://doi.org/10.3892/ijmm.2019.4226
  30. Xiao Z, Zhang M, Liu Y, Ren L. Botulinum toxin type a inhibits connective tissue growth factor expression in fibroblasts derived from hypertrophic scar. Aesthetic Plast Surg. 2011;35(5):802-807. https://doi.org/10.1007/s00266-011-9690-3
  31. Xiao Z, Zhang F, Lin W, Zhang M, Liu Y. Effect of botulinum toxin type A on transforming growth factor beta1 in fibroblasts derived from hypertrophic scar: a preliminary report. Aesthetic Plast Surg. 2010;34(4):424-427. https://doi.org/10.1007/s00266-009-9423-z
  32. Jung JA, Kim BJ, Kim MS, et al. Protective Effect of Botulinum Toxin against Ultraviolet-Induced Skin Pigmentation. Plast Reconstr Surg. 2019;144(2):347-356. https://doi.org/10.1097/PRS.0000000000005838
  33. Park JY, Sunga O, Wanitphakdeedecha R, Frevert J. Neurotoxin Impurities: A Review of Threats to Efficacy. Plast Reconstr Surg Glob Open. 2020;8(1):e2627. https://doi.org/10.1097/GOX.000000000000262
  34. Dressler D. Botulinum toxin drugs: brief history and outlook. J Neural Transm (Vienna). 2016;123(3):277-279. https://doi.org/10.1007/s00702-015-1478-1
  35. Samizadeh S, De Boulle K. Botulinum neurotoxin formulations: overcoming the confusion [published correction appears in Clin Cosmet Investig Dermatol. 2018 Dec 14;11:629]. Clin Cosmet Investig Dermatol. 2018;11:273-287. https://doi.org/10.2147/CCID.S156851
  36. Naumann M, Boo LM, Ackerman AH, Gallagher CJ. Immunogenicity of botulinum toxins. J Neural Transm (Vienna). 2013;120:275–90. https://doi.org/10.1007/s00702-012-0893-9.
  37. Timerbaeva S.L. The ineffectiveness of botulinum toxin therapy: old problem, new solutions. Nervnye bolezni. 2015;4:28-32. (In Russ.).
  38. Dover JS, Monheit G, Greener M, Pickett A. Botulinum Toxin in Aesthetic Medicine: Myths and Realities. Dermatol Surg. 2018;44(2):249-260. https://doi.org/10.1097/DSS.0000000000001277
  39. Orlova OR, Timerbayeva SL, Khatkova SE, Kostenko UV, Krasavina DA, Zakharov DV. Ratio of units of action of various botulinum neuroprotein preparations when used in neurological practice. Zhurnal nevrologii i psihiatrii. 2017;9:132-141. (In Russ.). https://doi.org/10.17116/jnevro201711791132-141
  40. Albrecht P, Jansen A, Lee JI, et al. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology. 2019;92(1): e48-e54. https://doi.org/10.1212/WNL.0000000000006688
  41. Fabbri M, Leodori G, Fernandes RM, et al. Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis. Neurotox Res. 2016;29(1):105-117. https://doi.org/10.1007/s12640-015-9565-5
  42. Dressler D, Hallett M. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc. Eur J Neurol. 2006;13 Suppl 1:11-15. https://doi.org/10.1111/j.1468-1331.2006.01439.x
  43. Bellows S, Jankovic J. Immunogenicity Associated with Botulinum Toxin Treatment. Toxins (Basel). 2019;11(9):491. Published 2019 Aug 26. https://doi.org/10.3390/toxins11090491
  44. Korolkova TN, Matytsin VO, Ivanov AM, Dovbeshko TG. The Role of antibody production in the formation of resistance to botulinum toxin A drugs a in aesthetic practice. Rossijskij zhurnal kozhnyh i venericheskih boleznej. 2013;6:43-47. (In Russ.).
  45. Dressler D, Bigalke H. Immunological aspects of botulinum toxin therapy. Expert Rev Neurother. 2017;17(5):487-494. https://doi.org/10.1080/14737175.2017.1262258
  46. Albrecht P, Jansen A, Lee JI, et al. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology. 2019;92(1): e48-e54. https://doi.org/10.1212/WNL.0000000000006688
  47. Dressler D, Pan L, Adib Saberi F. Antibody-induced failure of botulinum toxin therapy: re-start with low-antigenicity drugs offers a new treatment opportunity. J Neural Transm (Vienna). 2018;125(10):1481-1486. https://doi.org/10.1007/s00702-018-1911-3
  48. Kutschenko A, Bigalke H, Wegner F, Wohlfarth K. The role of human serum albumin and neurotoxin associated proteins in the formulation of BoNT/A products. Toxicon. 2019;168:158-163. https://doi.org/10.1016/j.toxicon.2019.07.005
  49. Mukai Y, Shimatani Y, Sako W, et al. Comparison between botulinum neurotoxin type A2 and type A1 by electrophysiological study in healthy individuals. Toxicon. 2014;81:32-36. https://doi.org/10.1016/j.toxicon.2013.12.012
  50. Kaji R, Miyashiro A, Sato N, Takeuchi T, Kaji S, Furumoto T. (2015) Randomised double-blind clinical trial of botulinum toxin subtype A2 (A2NTX) in comparison with subtype A1 (onabotulinumtoxinA). Neurology. 2015;84: 14 Suppl:4.333.
  51. Duarte GS, Castelão M, Rodrigues FB, et al. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev. 2016;10(10):CD004314. Published 2016 Oct 26. https://doi.org/10.1002/14651858.CD004314.pub3
  52. Bentivoglio AR, Del Grande A, Petracca M, Ialongo T, Ricciardi L. Clinical differences between botulinum neurotoxin type A and B. Toxicon. 2015; 107(Pt A):77-84. https://doi.org/10.1016/j.toxicon.2015.08.001
  53. Flynn TC, Clark RE 2nd. Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion. Dermatol Surg. 2003;29(5):519-522. https://doi.org/10.1046/j.1524-4725.2003.29124.x
  54. Dressler D, Pan L, Adib Saberi F. Antibody-Induced Failure of Botulinum Toxin Therapy: Re-Start with Low-Antigenicity Drugs Offers a New Treatment Opportunity. J Neural Transm. 2018;125:1481-1486. https://doi.org/10.1007/s00702-018-1911-3
  55. Hatheway CL. Botulism: the present status of the disease. Curr Top Microbiol Immunol. 1995;195:55-75. https://doi.org/10.1007/978-3-642-85173-5_3
  56. Zanetti G, Sikorra S, Rummel A, et al. Botulinum neurotoxin C mutants reveal different effects of syntaxin or SNAP-25 proteolysis on neuromuscular transmission. PLoS Pathog. 2017;13(8):e1006567. Published 2017 Aug 11. https://doi.org/10.1371/journal.ppat.1006567
  57. Eleopra R, Tugnoli V, Rossetto O, Montecucco C, De Grandis D. Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. Neurosci Lett. 1997;224(2):91-94. https://doi.org/10.1016/s0304-3940(97)13448-6.
  58. Eleopra R, Tugnoli V, Quatrale R, et al. Botulinum neurotoxin serotypes A and C do not affect motor units survival in humans: an electrophysiological study by motor units counting. Clin Neurophysiol. 2002;113(8):1258-1264. https://doi.org/10.1016/s1388-2457(02)00103-7
  59. Fonfria E, Maignel J, Lezmi S, et al. The Expanding Therapeutic Utility of Botulinum Neurotoxins. Toxins (Basel). 2018;10(5):208. https://doi.org/10.3390/toxins10050208
  60. Eleopra R, Tugnoli V, Quatrale R, Rossetto O, Montecucco C, Dressler D. Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type F. Neurotox Res. 2006;9(2-3):127-131. https://doi.org/10.1007/BF03033930
  61. Kutschenko A, Weisemann J, Kollewe K, et al. Botulinum neurotoxin serotype D — A potential treatment alternative for BoNT/A and B non-responding patients. Clin Neurophysiol. 2019;130(6):1066-1073. https://doi.org/10.1016/j.clinph.2019.02.007.
  62. Carruthers A, Sadick N, Brandt F, et al. Evolution of Facial Aesthetic Treatment Over Five or More Years: A Retrospective Cross-sectional Analysis of Continuous OnabotulinumtoxinA Treatment. Dermatol Surg. 2015;41(6): 693-701. https://doi.org/10.1097/DSS.0000000000000340
  63. Bertucci V, Solish N, Kaufman-Janette J, et al. DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). J Am Acad Dermatol. 2020;82(4):838-845. https://doi.org/10.1016/j.jaad.2019.06.1313
  64. Carruthers JD, Fagien S, Joseph JH, et al. DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2). Plast Reconstr Surg. 2020;145(1):45-58. https://doi.org/10.1097/PRS.0000000000006327
  65. Carruthers J, Solish N, Humphrey S, et al. Injectable DaxibotulinumtoxinA for the Treatment of Glabellar Lines: A Phase 2, Randomized, Dose-Ranging, Double-Blind, Multicenter Comparison With OnabotulinumtoxinA and Placebo. Dermatol Surg. 2017;43(11):1321-1331. https://doi.org/10.1097/DSS.0000000000001206
  66. Jankovic J, Truong D, Patel AT, et al. Injectable DaxibotulinumtoxinA in Cervical Dystonia: A Phase 2 Dose-Escalation Multicenter Study. Mov Disord Clin Pract. 2018;5(3):273-282. Published 2018 Apr 26. https://doi.org/10.1002/mdc3.12613
  67. Li T, Liu Y, Zhang W. Botulinum Toxin A Plays an Important Role in the Placement of Implants Deep Within the Pectoralis Major Muscle for Mammaplasty: A Systematic Review and Meta-analysis. Aesthetic Plast Surg. 2018;42(6):1519-1530. https://doi.org/10.1007/s00266-018-1203-1
  68. Singh JA. Botulinum toxin therapy for osteoarticular pain: an evidence-based review. Ther Adv Musculoskelet Dis. 2010;2(2):105-118. https://doi.org/10.1177/1759720X09357113
  69. Gerwin R. Botulinum toxin treatment of myofascial pain: a critical review of the literature. Curr Pain Headache Rep. 2012;16(5):413-422. https://doi.org/10.1007/s11916-012-0287-6.
  70. Mittal SO, Jabbari B. Botulinum Neurotoxins and Cancer-A Review of the Literature. Toxins (Basel). 2020;12(1):32. https://doi.org/10.3390/toxins12010032
  71. Yoelin SG, Dhawan SS, Vitarella D, Ahmad W, Hasan F, Abushakra S. Safety and Efficacy of EB-001, a Novel Type E Botulinum Toxin, in Subjects with Glabellar Frown Lines: Results of a Phase 2, Randomized, Placebo-Controlled, Ascending-Dose Study. Plast Reconstr Surg. 2018;142(6):847e-855e. https://doi.org/10.1097/PRS.0000000000005029
  72. Scheps D, López de la Paz M, Jurk M, Hofmann F, Frevert J. Design of modified botulinum neurotoxin A1 variants with a shorter persistence of paralysis and duration of action. Toxicon. 2017;139:101-108. https://doi.org/10.1016/j.toxicon.2017.09.006
  73. Pellett S, Tepp WH, Whitemarsh RC, Bradshaw M, Johnson EA. In vivo onset and duration of action varies for botulinum neurotoxin A subtypes 1-5. Toxicon. 2015;107(Pt A):37-42. https://doi.org/10.1016/j.toxicon.2015.06.021.
  74. Beer KR, Shamban AT, Avelar RL, Gross JE, Jonker A. Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines in Adult Subjects: Results From 2 Identical Phase III Studies. Dermatol Surg. 2019;45(11): 1381-1393. https://doi.org/10.1097/DSS.0000000000001903
  75. Khatkova SE, Kostenko EV, Pokhabov DV, Gustov AV, Kalyagin AN, Zhukova N.G. Safety and efficacy Assessment of the Russian botulinum toxin a Relatox® in comparison with Botox® in spasticity of the hand after ischemic stroke (multicenter randomized study). Nevrologiya, nejropsihiatriya, psihosomatika. 2017;9(1):71–77. (In Russ.). https://doi.org/10.14412/2074-2711-2017-1-71-77
  76. Orlova OR, Soyher MI, Soyher MG, Mingazova LR, Medovnikova DV, Soyher EM, Konovalova ZN, Alekseeva AYu. Bruxism: methods of application and results of treatment with botulinum neuroprotein (Relatox). Nervno-myshechnye bolezni. 2019;2:12-20. (In Russ.). https://doi.org/10.17650/2222-8721-2019-9-2-12-20
  77. Artemenko AR, Shavlovskaya OA, Mkhitaryan ER. Topical issues of the use of botulinum toxin type A in the treatment of blepharospasm. Klinicist. 2019;13(3-4):3-12. (In Russ.). https://doi.org/10.17650/1818-8338-2019-13-3-4-43-52
  78. Ileshina TV. Botulinum toxin therapy of the upper third of the face drug of domestic production Relatox. Clinical experience. Metamorfozy. 2015;9:88-92. (In Russ.).
  79. Ascher B, Rzany B, Kestemont P, et al. Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines. Aesthet Surg J. 2020;40(1):93-104. https://doi.org/10.1093/asj/sjz003
  80. Ascher B, Rzany B, Kestemont P, et al. Significantly Increased Patient Satisfaction Following Liquid Formulation AbobotulinumtoxinA Treatment in Glabellar Lines: FACE-Q Outcomes From a Phase 3 Clinical Trial [published online ahead of print, 2019 Sep 24]. Aesthet Surg J. 2019;sjz248. https://doi.org/10.1093/asj/sjz248
  81. Ascher B, Kestemont P, Boineau D, et al. Liquid Formulation of AbobotulinumtoxinA Exhibits a Favorable Efficacy and Safety Profile in Moderate to Severe Glabellar Lines: A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trial. Aesthet Surg J. 2018;38(2):183-191. https://doi.org/10.1093/asj/sjw272
  82. Poewe W, Burbaud P, Castelnovo G, et al. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial. Mov Disord. 2016;31(11):1649-1657. https://doi.org/10.1002/mds.26760
  83. Cohen JL. Evaluation of QM1114, a novel ready-to-use liquid botulinum toxin in aesthetic treatment of glabellar lines. Oral presentation at the 24th World Congress of Dermatology, Milan, 15 June 2019.
  84. Bakulev AL, Galustyan AN, Nezabudkina AS, Ryndyuk NN. Investigation of safety, tolerability and effectiveness of botulinum toxin type a in liquid form in patients with facial wrinkles and blepharospasm. Klinicheskaya dermatologiya i venerologiya. 2020;2:243-249. (In Russ.). https://doi.org/10.17116/klinderma202019021250
  85. Glogau R, Blitzer A, Brandt F, Kane M, Monheit GD, Waugh JM. Results of a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a botulinum toxin type A topical gel for the treatment of moderate-to-severe lateral canthal lines. J Drugs Dermatol. 2012;11(1):38-45.
  86. Glogau RG. Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: results of a randomized, blinded, vehicle-controlled study. Dermatol Surg. 2007;33(1 Spec No.):76-80. https://doi.org/10.1111/j.1524-4725.2006.32335.x
  87. Fonfria E, Maignel J, Lezmi S, et al. The Expanding Therapeutic Utility of Botulinum Neurotoxins. Toxins (Basel). 2018;10(5):208. https://doi.org/10.3390/toxins10050208
  88. Lueangarun S, Sermsilp C, Tempark T. Topical Botulinum Toxin Type A Liposomal Cream for Primary Axillary Hyperhidrosis: A Double-Blind, Randomized, Split-Site, Vehicle-Controlled Study. Dermatol Surg. 2018; 44(8):1094-1101. https://doi.org/10.1097/DSS.0000000000001532
  89. Carmichael NM, Dostrovsky JO, Charlton MP. Peptide-mediated transdermal delivery of botulinum neurotoxin type A reduces neurogenic inflammation in the skin. Pain. 2010;149(2):316-324. https://doi.org/10.1016/j.pain.2010.02.024.
  90. Zhang EZ, Tan S, Loh I. Botolinum toxin in rhinitis: Literature review and posterior nasal injection in allergic rhinitis. Laryngoscope. 2017;127(11):2447-2454. https://doi.org/10.1002/lary.26616
  91. Rohrbach S, Junghans K, Köhler S, Laskawi R. Minimally invasive application of botulinum toxin A in patients with idiopathic rhinitis. Head Face Med. 2009;5:18. Published 2009 Oct 16. https://doi.org/10.1186/1746-160X-5-18
  92. Ozcan C, Ismi O. Botulinum Toxin for Rhinitis. Curr Allergy Asthma Rep. 2016;16(8):58. https://doi.org/10.1007/s11882-016-0636-3
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.